CorDynamics to Exhibit Affordable Cardiovascular Safety and Discovery Solutions at Society of Toxicology Meeting in Baltimore

Chicago, IL (March 2009) - CorDynamics heads to the Society of Toxicology 48th Annual Meeting, March 15-19, 2009 at the Baltimore Convention Center. Dr. Michael R. Gralinski, CorDynamics CEO, will be among the experts in booth number 1436 available to meet with colleagues, clients and new customers.

"CorDynamics has exhibited at this meeting for the last six years," says Gralinski. "It's an ideal place for us to highlight the proven solutions we provide for cardiovascular safety and discovery questions. We've built our brand and client base on delivering decision-enabling isolated heart and screening telemetry results in a matter of days. These inherently affordable models maximize return on outsourcing spending at a time when R&D budgets have been cut throughout the biotech and pharmaceutical industry."

CorDynamics, Inc. is a comprehensive contract research organization and consulting group focused on examining the cardiovascular effects of emerging drug candidates. The company provides support with discovery and preclinical safety pharmacology studies along with lead optimization screening and consulting for more than 100 biopharmaceutical clients.

"CorDynamics also offers full-service GLP assessments needed for lead interrogation and regulatory submissions," says Gralinski. "Coupling our laboratories with our growing consulting operation, we truly are a ‘one-stop shop', and our clients have leveraged that to their advantage."

To learn more about the company, please visit our website at cordynamics.com. To schedule a private consultation with Dr. Gralinski please contact us at .

Contact:
Michael R. Gralinski, Ph.D., CorDynamics CEO